曲美他嗪对冠心病校正QT间期离散度的影响

目的通过研究曲美他嗪对冠心病校正QT间期离散度(QTcd)的影响,探讨曲美他嗪治疗对冠心病缺血心肌的保护作用.方法72例冠心病患者随机分为曲美他嗪治疗组和非曲美他嗪治疗组,观察其治疗前后QTcmax,QTcmin和QTcd的变化.另设正常人20例作对照组.结果冠心病患者QTcmax和QTcd较正常人增大,与治疗前相比,两组冠心病患者治疗后QTcmax和QTcd均有显著减少(P＜0.01).其中以曲美他嗪治疗组更明显.同时,两组间比较,治疗后QTcmax和QTcd有显著差异(P＜0.01),曲美他嗪治疗组减少更明显.结论冠心病患者QTcmax和QTcd较正常人增大,曲美他嗪通过缩小QTcmax而减少冠心病患者QTcd.

Influence of trimetazidine on QTcd in patients with coronary heart disease

Objective: To investigate the effect of trimetazidine on the corrected QT dispersion (QTcd) in patients with coronary heart disease.Methods:72 patients were divided into 2 groups at random: trimetazidine treatment group (conventional treatment trimetazidine) and conventional treatment group. Normal group(n=20) was regarded as control. The changes of QTcmax, QTcmin, QTcd were measured before and after treatment.Results:QTcmax and QTcd increased significantly in patients with coronary heart disease compared with those of the control. Both QTcmax, QTcd were decreased significantly in two groups after 7 days of treatment (P<0.01). But they decreased more obviously in trimetazidine treatment group than those in conventional group. There were significant differences in QTcmax and QTcd of two groups after treatment (P<0.01). QTcmax and QTcd decreased more significantly in trimetazidine treatment group than those in conventional group(P<0.01). Conclusions:QTcmax and QTcd increased apparently in patients with coronary heart disease. Trimetazidine can signifcantly decrease the QTcd of patients with coronary heart disease by shortening QTcmax.